Ignite Creation Date:
2024-05-06 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05268172
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2021-12-06
Brief Title:
IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites
Sponsor:
Affiliated Hospital of Jiangnan University
Organization:
Affiliated Hospital of Jiangnan University
Study Overview
Official Title:
Single-arm Open Multicenter Study of IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion Tumors
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties using a multicenter single-arm open design
Detailed Description:
Malignant pleural effusion is a common complication of malignant tumor which usually indicates that the patient has reached the advanced stage and about 30-40 of the patients are stubborn and refractory cases The lack of standard therapeutic drugs and protocols in clinical practice seriously affects the anti-tumor treatment effect quality of life and survival time of patients and the prognosis is poor IFN-γ can significantly induce the high expression of the costimulatory molecule ICAM-1 on tumor cells thereby enhancing the killing of TUMOR cells by T cells Moreover IFN-γ can enhance the activity of CAR T cells in the presence of PD-L1-PD-1 pathway and significantly improve the therapeutic effect of T cells on solid tumors IFN-γ is an approved clinical treatment with known side effects and well-established symptomatic treatment Although CIK is not a clinically approved drug it has been used on a large scale in China with good safety and has entered the medical insurance of some provinces and cities Tcm is an improved CIK cell and has good safety Many clinical studies have been carried out and no serious toxic and side effects have been observed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None